Agilent Technologies (NYSE:A - Free Report) had its price objective lowered by Jefferies Financial Group from $135.00 to $116.00 in a research report sent to investors on Monday,Benzinga reports. The brokerage currently has a hold rating on the medical research company's stock.
A has been the topic of a number of other reports. Wells Fargo & Company reduced their price objective on Agilent Technologies from $155.00 to $135.00 and set an "overweight" rating on the stock in a research note on Thursday, April 17th. StockNews.com raised Agilent Technologies from a "hold" rating to a "buy" rating in a research note on Tuesday, December 24th. TD Cowen raised their price objective on Agilent Technologies to $135.00 and gave the company a "buy" rating in a research note on Thursday, April 10th. Robert W. Baird reduced their price objective on Agilent Technologies from $161.00 to $159.00 and set an "outperform" rating on the stock in a research note on Thursday, February 27th. Finally, Barclays cut their target price on Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Agilent Technologies presently has an average rating of "Moderate Buy" and an average price target of $143.00.
Read Our Latest Research Report on A
Agilent Technologies Price Performance
A traded up $0.43 during trading on Monday, reaching $105.43. The stock had a trading volume of 151,400 shares, compared to its average volume of 1,861,192. The stock has a market cap of $30.06 billion, a PE ratio of 24.17, a PEG ratio of 2.90 and a beta of 1.19. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.66 and a current ratio of 2.20. Agilent Technologies has a one year low of $96.43 and a one year high of $155.35. The business has a 50-day moving average of $117.53 and a 200-day moving average of $131.61.
Agilent Technologies (NYSE:A - Get Free Report) last released its earnings results on Wednesday, February 26th. The medical research company reported $1.31 EPS for the quarter, beating analysts' consensus estimates of $1.27 by $0.04. The business had revenue of $1.68 billion for the quarter, compared to analysts' expectations of $1.67 billion. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. As a group, equities research analysts anticipate that Agilent Technologies will post 5.54 EPS for the current fiscal year.
Agilent Technologies Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Wednesday, April 23rd. Stockholders of record on Tuesday, April 1st were paid a $0.248 dividend. The ex-dividend date of this dividend was Tuesday, April 1st. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.94%. Agilent Technologies's dividend payout ratio is currently 22.76%.
Insider Transactions at Agilent Technologies
In other news, Director Daniel K. Podolsky sold 1,819 shares of the stock in a transaction on Monday, March 31st. The stock was sold at an average price of $116.46, for a total value of $211,840.74. Following the sale, the director now directly owns 35,737 shares of the company's stock, valued at approximately $4,161,931.02. This represents a 4.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Rodney Gonsalves sold 1,908 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $121.98, for a total value of $232,737.84. Following the sale, the vice president now directly owns 21,786 shares in the company, valued at $2,657,456.28. This trade represents a 8.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP boosted its position in Agilent Technologies by 0.6% in the fourth quarter. Wellington Management Group LLP now owns 9,306,805 shares of the medical research company's stock worth $1,250,276,000 after purchasing an additional 59,781 shares during the last quarter. Geode Capital Management LLC boosted its position in Agilent Technologies by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 7,002,671 shares of the medical research company's stock worth $938,291,000 after purchasing an additional 53,992 shares during the last quarter. Pictet Asset Management Holding SA raised its stake in shares of Agilent Technologies by 0.9% in the fourth quarter. Pictet Asset Management Holding SA now owns 5,213,739 shares of the medical research company's stock worth $700,414,000 after buying an additional 47,495 shares during the period. Deutsche Bank AG raised its stake in shares of Agilent Technologies by 0.9% in the fourth quarter. Deutsche Bank AG now owns 4,436,700 shares of the medical research company's stock worth $596,026,000 after buying an additional 38,348 shares during the period. Finally, Northern Trust Corp raised its stake in shares of Agilent Technologies by 12.3% in the fourth quarter. Northern Trust Corp now owns 4,192,790 shares of the medical research company's stock worth $563,259,000 after buying an additional 457,713 shares during the period.
Agilent Technologies Company Profile
(
Get Free Report)
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
Further Reading
Before you consider Agilent Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.
While Agilent Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
